These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 27432916)

  • 1. DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics.
    de Rosa N; Rodriguez-Bigas MA; Chang GJ; Veerapong J; Borras E; Krishnan S; Bednarski B; Messick CA; Skibber JM; Feig BW; Lynch PM; Vilar E; You YN
    J Clin Oncol; 2016 Sep; 34(25):3039-46. PubMed ID: 27432916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy.
    Cercek A; Dos Santos Fernandes G; Roxburgh CS; Ganesh K; Ng S; Sanchez-Vega F; Yaeger R; Segal NH; Reidy-Lagunes DL; Varghese AM; Markowitz A; Wu C; Szeglin B; Sauvé CG; Salo-Mullen E; Tran C; Patel Z; Krishnan A; Tkachuk K; Nash GM; Guillem J; Paty PB; Shia J; Schultz N; Garcia-Aguilar J; Diaz LA; Goodman K; Saltz LB; Weiser MR; Smith JJ; Stadler ZK
    Clin Cancer Res; 2020 Jul; 26(13):3271-3279. PubMed ID: 32144135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mismatch Repair System Deficiency Is Associated With Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.
    Meillan N; Vernerey D; Lefèvre JH; Manceau G; Svrcek M; Augustin J; Fléjou JF; Lascols O; Simon JM; Cohen R; Maingon P; Bachet JB; Huguet F
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):824-833. PubMed ID: 31404579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer].
    Qin Q; Ying J; Lyu N; Guo L; Zhi W; Zhou A; Wang J
    Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):844-8. PubMed ID: 25620482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mismatch repair system deficiency is associated with chemoradiotherapy resistance in locally advanced rectal adenocarcinoma patients.
    Ni K; Zhan Y; Liu Z; Zhao XZ; Wang W; Wang G; Zhang Z; Li G; Zhang X; Zhang C
    J Surg Oncol; 2022 Mar; 125(4):692-702. PubMed ID: 34918842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
    Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
    Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microsatellite instability testing and its role in the management of colorectal cancer.
    Kawakami H; Zaanan A; Sinicrope FA
    Curr Treat Options Oncol; 2015 Jul; 16(7):30. PubMed ID: 26031544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
    Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
    Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do microsatellite instability (MSI) and deficient mismatch repair (dMMR) affect the pathologic complete response (pCR) in patients with rectal cancer who received neoadjuvant treatment?
    Acar T; Acar N; Kamer E; Tekindal MA; Cengiz F; Kar H; Atahan K; Haciyanli M
    Updates Surg; 2020 Mar; 72(1):73-82. PubMed ID: 31863279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characteristics and Outcomes of Treatment in Patients with Stage IV Colorectal Cancer with Mismatch Repair Deficiency].
    Ishibashi K; Chika N; Suzuki O; Ito T; Amano K; Kumamoto K; Fukuchi M; Kumagai Y; Mochiki E; Ishida H
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1711-1714. PubMed ID: 28133107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokeratin 7 Expression and Mismatch Repair Status for Survival Prediction in Patients With Low Rectal Cancer After Neoadjuvant Therapy.
    Shi S; Zhou M; Wang G; Xu J; Zhang D; Zheng M; Zhang S
    Cancer Control; 2023; 30():10732748231214936. PubMed ID: 38008773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy.
    Hall MD; Schultheiss TE; Smith DD; Fakih MG; Wong JY; Chen YJ
    Acta Oncol; 2016 Dec; 55(12):1392-1399. PubMed ID: 27762654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymidine phosphorylase and hypoxia-inducible factor 1-α expression in clinical stage II/III rectal cancer: association with response to neoadjuvant chemoradiation therapy and prognosis.
    Lin S; Lai H; Qin Y; Chen J; Lin Y
    Int J Clin Exp Pathol; 2015; 8(9):10680-8. PubMed ID: 26617778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy?
    Kuo LJ; Liu MC; Jian JJ; Horng CF; Cheng TI; Chen CM; Fang WT; Chung YL
    Ann Surg Oncol; 2007 Oct; 14(10):2766-72. PubMed ID: 17551794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Less than 12 nodes in the surgical specimen after total mesorectal excision following neoadjuvant chemoradiation: it means more than you think!
    de Campos-Lobato LF; Stocchi L; de Sousa JB; Buta M; Lavery IC; Fazio VW; Dietz DW; Kalady MF
    Ann Surg Oncol; 2013 Oct; 20(11):3398-406. PubMed ID: 23812804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer.
    Mace AG; Gantt GA; Skacel M; Pai R; Hammel JP; Kalady MF
    Dis Colon Rectum; 2013 Nov; 56(11):1217-27. PubMed ID: 24104995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
    Balboa E; Duran G; Lamas MJ; Gomez-Caamaño A; Celeiro-Muñoz C; Lopez R; Carracedo A; Barros F
    Pharmacogenomics; 2010 Jun; 11(6):747-61. PubMed ID: 20504250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.